Recent News Releases

For investor-related news, see our ASX releases here.

Month Year

Email Alerts

Dec 7, 2016

EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Dec 3, 2016

CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.

03 Dec 2016 Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly...
Dec 2, 2016

The Lancet Respiratory Medicine Publishes RAPID Extension Study Data Confirming Disease-modifying Effect of Respreeza® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.

02 Dec 2016 Global biotherapeutics leader CSL Behring announced today that data from the RAPID Open Label Extension study, conducted in patients with alpha-1 antitrypsin deficiency (AATD),...
Nov 28, 2016

FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Nov 24, 2016

Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Release

Show per page

Filter by Company:

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa